
{
  "drug_name": "Pristinamycin",
  "tradename": "Pyostacine",
  "usage_and_dosing": {
    "description": "Pristinamycin is a mixture of pristinamycin IA and pristinamycin IIA.",
    "notes": [
      "Pristinamycin IA (PIA) is a group B streptogramin, pristinamycin IIA (PIIA) is a group A streptogramin.",
      "Group A and B streptogramins bind to the 50S subunit of the bacterial ribosome. Individually they are bacteriostatic, but in combination may be bactericidal.",
      "Available in Europe (France, Belgium), but not marketed in the U.S."
    ],
    "adult_dose": "2-4 gm/day (divided q8-12h).",
    "pediatric_dose": {
      "dose": "50-100 mg/kg/day (divided q8h)"
    }
  },
  "renal_adjustment": {
    "body_weight_and_creatinine_clearance_calculations": true,
    "half_life_normal": {
      "pia": 4.03,
      "piia": 2.83
    },
    "half_life_esrd": {
      "pia": "Unchanged",
      "piia": "Unchanged"
    },
    "dose_renal_function_normal": "2-4 gm/day po (divided q8-12h)",
    "crcl_or_egfr": "No dosage adjustment for renal impairment",
    "hemodialysis": "No data",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment": "No dosage adjustment",
    "moderate_impairment": "No dosage adjustment",
    "severe_impairment": "No dosage adjustment"
  },
  "adverse_effects": [
    "GI (nausea, vomiting)",
    "Hypersensitivity reactions (uncommon)",
    "Pseudomembranous colitis"
  ],
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "24-hr AUC/MIC",
    "preparations": "Tab (250, 500 mg)",
    "food_recs": "Tab + food",
    "oral_absorption": "No data",
    "tmax_hr": {
      "pia": 3.25,
      "piia": 3.08
    },
    "peak_serum_conc": {
      "pia": "0.76 (2 gm po, SD)",
      "piia": "0.58 (2 gm po, SD)"
    },
    "peak_urine_conc": "No data",
    "protein_binding": "No data",
    "volume_of_distribution": "No data",
    "avg_serum_t1_2": {
      "pia": 4.03,
      "piia": 2.83
    },
    "elimination": "Biliary",
    "bile_penetration": "No data",
    "csf_blood": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc": {
      "pia": "2.2 (2 gm po, 0-inf)",
      "piia": "1.21 (2 gm po, 0-inf)"
    }
  },
  "enzyme_transporter_mediated_interactions": {
    "cyp450s_inhibited": [
      "CYP3A4"
    ],
    "impact_on_serum_drug_concentrations": "↑"
  },
  "major_drug_interactions": [
    {
      "drug": "Cyclosporine",
      "effect": "↑ cyclosporine",
      "management": "Monitor, adjust dosage"
    },
    {
      "drug": "Tacrolimus",
      "effect": "↑ tacrolimus",
      "management": "Monitor, adjust dosage"
    }
  ],
  "comments": [
    "Reference for PK data: J Antimicrob Chemother 25:651, 1990.",
    "Reported effective in treating macrolide and quinolone-resistant strains of Mycoplasma genitalium (Clin Infect Dis 60:1228, 2015; Emerg Infect Dis 24:328, 2018)."
  ]
}
